Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab – Results of the randomised GeparQuinto study (GBG 44)
作者： Jens Huober , Peter A. Fasching , Claus Hanusch , Mahdi Rezai , Holger Eidtmann
DOI: 10.1016/J.EJCA.2013.02.027
关键词:
摘要: … -positive trastuzumab resistant breast cancer.21, 22 Since … This report investigates the efficacy in terms of pCR rates of … our study no clinical trial reporting on everolimus in combination …
elsevier.com
sci-hub.se 参考文章(31)
M Campone, V Levy, E Bourbouloux, D Berton Rigaud, D Bootle, C Dutreix, U Zoellner, N Shand, F Calvo, E Raymond, Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours British Journal of Cancer. ,vol. 100, pp. 315- 321 ,(2009) , 10.1038/SJ.BJC.6604851
Brian M. Slomovitz, Karen H. Lu, Taren Johnston, Robert L. Coleman, Mark Munsell, Russell R. Broaddus, Cheryl Walker, Lois M. Ramondetta, Thomas W. Burke, David M. Gershenson, Judith Wolf, A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer. ,vol. 116, pp. 5415- 5419 ,(2010) , 10.1002/CNCR.25515
G von Minckwitz, JU Blohmer, S Costa, C Denkert, H Eidtmann, W Eiermann, B Gerber, C Hanusch, J Hilfrich, J Huober, C Jackisch, M Kaufmann, S Kümmel, S Paepke, A Schneeweiss, M Untch, DM Zahm, K Mehta, S Loibl, S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients - Results of the GeparTrio Trial. Cancer Research. ,vol. 71, ,(2011) , 10.1158/0008-5472.SABCS11-S3-2
Ruth O'Regan, Natalyn Nicole Hawk, mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy Expert Opinion on Therapeutic Targets. ,vol. 15, pp. 859- 872 ,(2011) , 10.1517/14728222.2011.575362
Jong Woo Lee, Young Hwa Soung, Su Young Kim, Hae Woo Lee, Won Sang Park, Suk Woo Nam, Sang Ho Kim, Jung Young Lee, Nam Jin Yoo, Sug Hyung Lee, PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas Oncogene. ,vol. 24, pp. 1477- 1480 ,(2005) , 10.1038/SJ.ONC.1208304
Jens Huober, Gunter von Minckwitz, Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years? Breast Care. ,vol. 6, pp. 419- 426 ,(2011) , 10.1159/000335347
Michael Untch, Sibylle Loibl, Joachim Bischoff, Holger Eidtmann, Manfred Kaufmann, Jens-Uwe Blohmer, Jörn Hilfrich, Dirk Strumberg, Peter A Fasching, Rolf Kreienberg, Hans Tesch, Claus Hanusch, Bernd Gerber, Mahdi Rezai, Christian Jackisch, Jens Huober, Thorsten Kühn, Valentina Nekljudova, Gunter von Minckwitz, Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial Lancet Oncology. ,vol. 13, pp. 135- 144 ,(2012) , 10.1016/S1470-2045(11)70397-7
T Bachelot, C Bourgier, C Cropet, J-P Guastalla, J-M Ferrero, C Leger-Falandry, P Soulie, J-C Eymard, M Debled, D Spaeth, E Legouffe, T Delozier, C El Kouri, J. Chidiac, Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI). Cancer Research. ,vol. 70, ,(2010) , 10.1158/0008-5472.SABCS10-S1-6
David M. Sabatini, mTOR and cancer: insights into a complex relationship. Nature Reviews Cancer. ,vol. 6, pp. 729- 734 ,(2006) , 10.1038/NRC1974
Funda Meric-Bernstam, Ana Maria Gonzalez-Angulo, Targeting the mTOR Signaling Network for Cancer Therapy Journal of Clinical Oncology. ,vol. 27, pp. 2278- 2287 ,(2009) , 10.1200/JCO.2008.20.0766